CXCL14 production promoter

Abstract

To provide a novel CXCL14 production promoter.SOLUTION: The present invention provides a CXCL14 production promoter containing Camellia japonica seed extract as an active ingredient. By promoting CXCL14 production, it is effective in activating an immune function.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to a CXCL14 production promoter, and more specifically, to a CXCL14 production promoter containing camellia seed extract as an active ingredient. [Background technology]

[0002] CXCL14 is a chemokine that promotes the migration of immature dendritic cells and NK cells, and is also produced in large amounts by keratinocytes. Recent studies have reported that it may be an important factor in maintaining Langerhans cells, which are important in the immune response of the skin (Non-Patent Document 1). Therefore, it is desirable to search for substances that activate the immune function of the skin by promoting CXCL14. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] International Publication No. 2020 / 091070 [Patent Document 2] JP 2011-80409 A [Non-patent literature]

[0004] [Non-Patent Document 1] J Invest Dermatol. 2020 July; 140(7): 1327-1334. doi:10.1016 / j.jid.2019.11.017. Summary of the Invention [Problem to be solved by the invention]

[0005] An object of the present invention is to provide a novel agent for promoting CXCL14 production. [Means for solving the problem]

[0006] As a result of extensive research into the effects of various ingredients as CXCL14 production promoters, the inventors have found that camellia seed extract is particularly effective as a CXCL14 production promoter, leading to the completion of the following invention: (1) A CXCL14 production promoter containing camellia seed extract as an active ingredient. (2) A CXCL14 production promoter according to (1) for promoting CXCL14 production in keratinocytes. Effect of the Invention

[0007] CXCL14 production can be promoted by administration of the CXCL14 production promoter of the present invention. According to the present invention, a composition containing the CXCL14 production promoter can be provided. By promoting CXCL14 production, immune function can be activated through the maintenance of Langerhans cells. [Brief description of the drawings]

[0008] [Figure 1] Figure 1 shows the results of comparing the amount of CXCL14 produced (pg / mL) in keratinocytes treated with Camellia seed extract with the control without treatment (n=4, Mann-Whitney U test, *:p<0.05). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present invention provides a CXCL14 production promoter comprising camellia seed extract as an active ingredient.

[0010] CXCL14 production can be promoted by administration of the CXCL14 production promoter of the present invention. As mentioned above, it has been reported that CXCL14 is useful for maintaining Langerhans cells and activating immune function (Non-Patent Document 1). Therefore, if the camellia seed extract discovered by the present inventors can promote CXCL14 production, it is expected that immune function will be activated through the maintenance of Langerhans cells.

[0011] Promotion of CXCL14 production can mean, for example, that when a CXCL14 production promoter is administered, the amount of CXCL14 produced is increased with a statistically significant difference (e.g., Mann-Whitney U test) at a significance level of 5%, for example, compared to a state (control) in which the CXCL14 production promoter is not administered.

[0012] The present invention also provides an immune function activator that contains camellia seed extract as an active ingredient and activates immune function through promotion of CXCL14 production, as well as a Langerhans cell maintenance agent that contains camellia seed extract as an active ingredient and maintains Langerhans cells through promotion of CXCL14 production. The present invention also provides a composition containing a CXCL14 production promoter, immune function activator, or Langerhans cell maintenance agent that contains camellia seed extract as an active ingredient. The composition of the present invention may be a composition for immune activation or maintenance of Langerhans cells through promotion of CXCL14 production. In one aspect of such an embodiment, the immune function activation is activation of immune function of the skin. In one aspect of such an embodiment, the immune function activation is activation of immune function of the skin by promoting CXCL14 production in keratinocytes. In one aspect of such an embodiment, the maintenance of Langerhans cells is maintenance of Langerhans cells in the skin, preferably in keratinocytes.

[0013] Camellia seed extract is an extract obtained by extracting the seeds of Camellia japonica, and is expressed as Camellia japonica Seed Extract in the display name / INCI name (International Nomenclature of Cosmetic Ingredients) used for displaying all ingredients of cosmetics as specified by the Japan Cosmetic Industry Association. Camellia seed extract is known to have effects such as alternative autophagy induction and suppression of ultraviolet ray-induced inflammation (Patent Document 1). It has also been described that camellia plant extract has an anti-inflammatory effect, and the suppression effect of camellia flower extract on the activation of inflammatory cytokine expression has been demonstrated (Patent Document 2). However, it has not been reported that camellia seed extract has a high CXCL14 production promoting effect.

[0014] The method for extracting camellia seed extract can be carried out, for example, by solvent extraction. In the case of solvent extraction, camellia seeds are dried as necessary, and further chopped or crushed as necessary, and then extracted with an aqueous extractant, water, for example, cold water, warm water, or hot water at or below the boiling point, or a water-containing organic solvent, for example, water-containing ethanol, water-containing methanol, water-containing ether, water-containing 1,3-butylene glycol, etc., or an organic solvent, for example, ethanol, methanol, ether, 1,3-butylene glycol, etc., selected appropriately according to the properties of the raw materials and the use of the composition, at room temperature or with heating. However, the extraction method is not limited to solvent extraction, and may be a conventional method known in the art, and the extraction method and form of the extract used in the present invention are optional as long as they do not impair the effects of the present invention. The form of the extract may be not only the extract itself, but also a product appropriately diluted or concentrated by a conventional method, and may further be a powder or lump-like solid obtained by drying the extract, or a product appropriately diluted or concentrated by a conventional method from the squeezed juice.

[0015] As an example of the water-containing organic solvent, a water-containing lower alcohol (e.g., C1 to C4) such as water-containing 1,3-butylene glycol may be used, and in this case, the water content may be, for example, 0 to 10 v / v%, 10 to 40 v / v%, 20 to 30 v / v%, 30 to 40 v / v%, 30 to 50 v / v%, 60 to 70 v / v%, 50 to 80 v / v%, 80 to 99.5 v / v%, etc.

[0016] The CXCL14 production promoter, immune function activator, or Langerhans cell maintenance agent of the present invention (hereinafter collectively referred to as "the agent of the present invention") may be incorporated into compositions such as cosmetics, medicines, and quasi-drugs and administered topically to animals such as humans, or may be incorporated into compositions such as various foods, food and drink, and nutritional supplements such as supplements and administered orally to animals such as humans, or may be administered to animals such as humans as a pharmaceutical preparation. The form of topical administration may be selected from any of a variety of forms, such as creams, emulsions, liquids, sheets, sprays, and gels. The form of oral administration may be selected from any of a variety of forms, such as tablets, beverages, and powders. However, the administration form is not limited to those described above.

[0017] The cosmetic composition of the present invention may be various types of cosmetics such as emulsion, cream, beauty essence, lotion, pack, face wash, soap, body soap, shampoo, etc., and may be in various forms such as liquid, emulsion, cream, solid, sheet, spray, gel, foam, powder, etc. The food composition of the present invention may be a powder, beverage, or tablet, and may be in various forms such as powder, liquid, solid, granule, particulate, paste, gel, etc.

[0018] The frequency of application can be selected arbitrarily, such as once every 4 weeks, once every 2 weeks, once a week, once every 3 days, once every 2 days, once a day, twice a day, three times a day, four times a day, five times a day, or as needed, but is not limited to these.

[0019] The agent or composition of the present invention preferably contains camellia seed extract in an amount that sufficiently exhibits the effect of promoting CXCL14 production, and this can be appropriately determined depending on the type, purpose, form, method of use, etc. For example, the amount of camellia seed extract (dry weight) per total weight of the agent or composition of the present invention can be 0.0001-0.0005 wt%, 0.0005-0.001 wt%, 0.001-0.005 wt%, 0.005-0.01 wt%, 0.01-0.05 wt%, 0.05-0.1 wt%, 0.1-0.5 wt%, 0.5-1.0 wt%, 1.0-5.0 wt%, 5.0-10.0 wt%, 10.0-50.0 wt%, or 50.0-100.0 wt%. In some embodiments, the agent of the present invention may contain camellia seed extract as an active ingredient, for example, 10% by weight or more, 20% by weight or more, 30% by weight or more, 40% by weight or more, 50% by weight or more, 60% by weight or more, 70% by weight or more, 80% by weight or more, 90% by weight or more, 95% by weight or more, or 99% by weight or more. In some embodiments, the agent of the present invention may consist of camellia seed extract.

[0020] The agent or composition of the present invention may contain additives selected arbitrarily as necessary. The additives may include excipients and the like.

[0021] The excipient may be any one that is normally used when the desired dosage form is prepared, and examples thereof include starches such as wheat starch, rice starch, corn starch, potato starch, dextrin, and cyclodextrin, crystalline celluloses, sugars such as lactose, glucose, sugar, reduced maltose, starch syrup, fructooligosaccharides, and emulsified oligosaccharides, and sugar alcohols such as sorbitol, erythritol, xylitol, lactitol, and mannitol. These excipients may be used alone or in combination of two or more.

[0022] Other additives may be appropriately selected from known additives such as colorants, preservatives, thickeners, binders, disintegrants, dispersants, stabilizers, gelling agents, antioxidants, surfactants, preservatives, pH adjusters, oils, water, alcohols, chelating agents, silicones, ultraviolet absorbers, moisturizers, fragrances, various medicinal ingredients, preservatives, and neutralizing agents.

[0023] The present invention also provides a method for activating immune function through promotion of CXCL14 production by applying camellia seed extract. The present invention also provides a method for activating immune function through promotion of CXCL14 production by applying camellia seed extract. The method for activating immune function of the present invention is a method for cosmetic purposes and may not be a treatment by a doctor or medical professional.

[0024] Furthermore, the present invention also provides a use of the Camellia seed extract in the manufacture of a medicine for activating immune function.The present invention also provides a Camellia seed extract for use in activating immune function, preferably, the immune function is an immune function of the skin, and the immune function of the skin is activated by promoting CXCL14 production in keratinocytes. EXAMPLES

[0025] The present invention will now be described in more detail with reference to examples, although the present invention is not limited thereto.

[0026] 1. Sample Preparation The camellia seed extracts used as samples were Yuka Sangyo Co., Ltd.'s camellia seed extract (extract of camellia seeds extracted with 1,3-butylene glycol), camellia leaf extract (extract of camellia leaves extracted with 1,3-butylene glycol), and camellia flower extract (extract of camellia flowers extracted with 1,3-butylene glycol).

[0027] 2. Culture of normal human epidermal keratinocytes and evaluation of camellia extract Normal human epidermal keratinocytes (Kurabo Industries, product number KK-4009) were cultured in EpiLife medium (GIBCO, product number MEPI500CA), a medium for proliferation of epidermal keratinocytes, and 5 × 10 4 The cells were seeded at 1000 cells / ml and cultured at 37°C for 48 hours until the cells became subconfluent. After 48 hours of culture, the medium was replaced with one containing 0.01% by weight of camellia seed extract, camellia leaf extract, or camellia flower extract per medium. After medium replacement, the cells were cultured for an additional 48 hours, and the culture supernatant was collected. As a control, the cells were cultured under the same conditions in a medium of the same composition except that the above samples were not added.

[0028] 3. Quantification of CXCL14 The concentration of CXCL14 in the culture supernatant was evaluated using Human CXCL14 / BRAK DuoSet ELISA (R&D). The rate of change relative to the control was calculated, and the Mann-Whitney U test was used to test for statistical significance.

[0029] The results are shown in Figure 1. As shown in Figure 1, it was confirmed that the camellia seed extract had a significantly higher CXCL14 production promoting effect than the control. It was also confirmed that the CXCL14 production promoting effect of the camellia seed extract was significantly higher than that of the camellia leaf or flower extract. [Industrial Applicability]

[0030] The present invention is capable of promoting CXCL14 production by administration of a CXCL14 production promoter containing camellia seed extract as an active ingredient, and is effective in activating immune function through promotion of CXCL14 production. In particular, activation of skin immune function is expected by promoting CXCL14 production in keratinocytes.

Claims

1. A CXCL14 production promoter comprising camellia seed extract as an active ingredient.

2. The CXCL14 production promoter according to claim 1, for promoting the promotion of CXCL14 production in keratinocytes.

Images